• 18206 Citations
  • 66 h-Index
1987 …2019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Viviana Enrica Galimberti is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 23 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Breast Medicine & Life Sciences
Radiotherapy Medicine & Life Sciences
Dissection Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Segmental Mastectomy Medicine & Life Sciences
Sentinel Lymph Node Biopsy Medicine & Life Sciences
Mastectomy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1987 2019

Secondary breast angiosarcoma: A multicentre retrospective survey by the national Italian association of Breast Surgeons (ANISC)

Taffurelli, M., Pellegrini, A., Meattini, I., Orzalesi, L., Tinterri, C., Roncella, M., Terribile, D., Caruso, F., Tazzioli, G., Pollini, G., Friedman, D., Mariotti, C., Cianchetti, E., Cabula, C., Thomas, R., Cedolini, C., Rovera, F., Grassi, M., Lucani, G., Cappella, A. & 5 others, Bortul, M., Stacul, G., Scarabeo, F., Procaccini, E. & Galimberti, V., Jun 1 2019, In : Breast. 45, p. 56-60 5 p.

Research output: Contribution to journalArticle

Breast
Mastectomy
Hemangiosarcoma
Lymphedema
Survival
26 Citations (Scopus)

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

International Breast Cancer Study Group Trial 23-01, Oct 1 2018, In : The Lancet Oncology. 19, 10, p. 1385-1393 9 p.

Research output: Contribution to journalArticle

Neoplasm Micrometastasis
Dissection
Breast Neoplasms
Disease-Free Survival
cyhalothrin

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

International Breast Cancer Study Group Trial 23-01, Oct 1 2018, In : The Lancet Oncology. 19, 10, p. 1385-1393 9 p.

Research output: Contribution to journalArticle

Neoplasm Micrometastasis
Dissection
Breast Neoplasms
Disease-Free Survival
cyhalothrin
Germ-Line Mutation
Missense Mutation
Ovarian Neoplasms
Mutation
BRCA2 Gene